Daniel Tarquinio, DO
Neurology with Special Qualifications in Child Neurology · Gainesville, GANPI 1427131168
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,009 of the $50,130 with a category attached, or 63.9%. Neurelis, Inc. accounts for 67.5% of it on its own, with 29 other manufacturers making up the rest. Among neurology with special qualifications in child neurology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $184.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$34K
- AbbVie$8K
- Acadia Pharmaceuticals Inc$3K
- Cipla USA Inc.$3K
- Pfizer$524
- Immedica Pharma US, Inc.$513
- plus $2K from 24 others
Across 60 payments — averaging $10,995 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurelis, Inc.$366K
- Ultragenyx Pharmaceutical Inc.$189K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$61K
- Takeda Pharmaceuticals U.S.A., Inc.$37K
- Biogen$4K
- Immedica Pharma US, Inc.$2K
What the payments were for
- Consulting fees$12,58025%
- Speaking & faculty fees$32,00964%
- Travel & lodging$6021%
- Food & beverage$4,93910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 64 | $33,838 |
| AbbVie | 72 | $7,751 |
| Acadia Pharmaceuticals Inc | 18 | $2,954 |
| Cipla USA Inc. | 1 | $2,567 |
| Pfizer | 36 | $524 |
| Immedica Pharma US, Inc. | 2 | $513 |
| UCB, Inc. | 14 | $367 |
| SK Life Science, Inc. | 9 | $257 |
| Jazz Pharmaceuticals Inc. | 5 | $241 |
| Argenx US, Inc. | 7 | $174 |
| Teva Pharmaceuticals USA, Inc. | 7 | $162 |
| Novartis | 4 | $82 |
| Lilly USA, LLC | 4 | $77 |
| Eisai Inc. | 3 | $74 |
| PTC Therapeutics, Inc. | 1 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Biogen | 2 | $50 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Kyowa Kirin, Inc. | 3 | $44 |
| Amgen | 2 | $41 |
| AstraZeneca | 2 | $34 |
| Abbott | 1 | $32 |
| Lundbeck LLC | 1 | $29 |
| Corium, LLC | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Bioventus LLC | 1 | $15 |
| Insightec,inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,130 in reported general payments places this provider in the 90th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
See all neurology with special qualifications in child neurology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $370,817 |
| IngrezzaValbenazine Tosylate | 16 | $204,076 |
| TecfideraDimethyl Fumarate | 11 | $96,598 |
| Aimovig AutoinjectorErenumab-Aooe | 70 | $58,003 |
| XcopriCenobamate | 41 | $41,226 |
| EpidiolexCannabidiol (Cbd) | 13 | $38,642 |
| BotoxOnabotulinumtoxina | 13 | $32,534 |
| UbrelvyUbrogepant | 21 | $29,660 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $25,913 |
| Nurtec OdtRimegepant Sulfate | 16 | $22,691 |
| NeuproRotigotine | 17 | $20,596 |
| ValtocoDiazepam | 23 | $18,062 |
| Ajovy SyringeFremanezumab-Vfrm | 24 | $17,028 |
| Emgality PenGalcanezumab-Gnlm | 13 | $10,192 |
| Memantine Hcl | 328 | $9,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $50 | $96,59811 claims |
| AbbVieBotox, Ubrelvy | $7,751 | $62,19434 claims |
| SK Life Science, Inc.Xcopri | $257 | $41,22641 claims |
| PfizerNurtec Odt, Dilantin | $524 | $24,73531 claims |
| UCB, Inc.Neupro | $367 | $20,59617 claims |
| Neurelis, Inc.Valtoco | $33,838 | $18,06223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
Other neurology with special qualifications in child neurology in Gainesville
- John HemphillSavannah$2M
- Chaouki KhouryAtlanta$978K
- Katherine MoretzSavannah$144K
- Yong ParkAugusta$78K
- Han PhanAtlanta$44K
- Raymond ChengAtlanta$40K
- Sonam BhallaAtlanta$23K
- Cherise FrazierAtlanta$9K
- Enrique FernandezBrunswick$8K
- Elizabeth SekulAugusta$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.